Mumakore achangopfuura, mhedzisiro ye immune checkpoint inhibitors pakurapa kweHodgkin's lymphoma (HL) inoyevedza, asi hosha ichiri kuda kukurirwa zvakanyanya. Sachigaro weMayo Clinic yeLymphoma Group Ansell akati isu tiri kudzidza kubva kubiology yeHodgkin's lymphoma uye nekupa mimwe mikana yekurapa lymphoma mune ramangwana.
We talk about the effectiveness of PD-L1 blockade in HL, looking for deeper solutions, alternative drug combinations that are making progress, and potential pathways for future discovery.
Ansell akataura nyaya yemurwere ane HL. Akamudana husiku humwe uye akazivisa kuti aishandisa nivolumab (Opdivo) kurapwa kunoshanda. Kunze kwezvimwe zviratidzo, murwere aive awedzerawo ma "lymph node" uye asisiri kumwe kunhuwa. Chokwadi, zvakazoitika kuti HL yake yaizorodza, asi mushure memakore maviri ekurapwa, haina kunyangarika zvachose.
Semudzvinyiriri, Ansell akati akaodzwa mwoyo zvikuru. Zviripachena, kunyangwe kurapa kwaive kushanda, maseru ezvirwere zvemuviri haana kuratidza zvakakwana immune memory. Ansell akawana chimwe chinhu chinokanganisa ndechekuti zvinoita sekunge varwere vanofanira kurapwa nenzira iyi muhupenyu hwavo hwese.
Kuti uongorore humbowo hwenivolumab sekutarisa kwekutarisa, iyo-ruoko-chikamu II CheckMate 205 yakadzokororwa / inokonzeresa yechinyakare Hodgkin lymphoma (cHL) kuyedza, iyo yakasimbisa huwandu hwakazara hwekupindura (ORR) mushure mekuteedzana kwepakati pemwedzi gumi nesere) 18%, iyo yepakati mediyamu yekupindura yaive 69 mwedzi, uye wepakati wepasirose-kusaenderera kupona yaive 16.6 mwedzi.
The KEYNOTE-087 single-arm phase II study of pembrolizumab (Keytruda) for this disease, in which the ORR of the drug was 69.0%, and the complete remission rate (CR) was 22.4%, 31 patients responded ≥ 6 months.
Chikamu cheI JAVELIN kudzidza kwakayedza avelumab (Bavencio) seyakasarudzika bhainda yePD-L1 mu r / r HL. Ansell akataura kuti iyo ORR yevarwere vese ve31 yaive 41.9% uye chikamu chemhinduro yaive 25.8%. Iyo yepakati yekuita nguva ndeye 1.5 mwedzi
Iyi nzira yakaedzwa nekubatanidza immune checkpoint inhibitors nivolumab uye ipilimumab (Yervoy). Nivolumab inoshanda sePD-L1 blocker, ipilimumab inotarisa immune system kudzika-kutonga iro basa reCTLA-4. MuCheckMate 039, izvi zvakakonzera ORR ye74% (n = 23) uye CR chiyero che19% (n = 6). Parizvino, immune checkpoint inhibitors yakawana mhedzisiro mukurapa kweCHL, asi pachine nzira refu yekufamba, uye hatigone kuva netariro isina tariro.
